Increased Glycogen Synthase Kinase-3β mRNA Level in the Hippocampus of Patients with Major Depression: A Study Using the Stanley Neuropathology Consortium Integrative Database
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaGlycogen synthase kinase-3β (GSK-3β) has become recognized as a broadly influential enzyme affecting diverse range of biological functions, including gene expression, cellular architecture, and apoptosis. The results of previous studies suggest that GSK-3β activity may be increased in the brain of patients with major depressive disorders (MDD). A recent animal study reported increased GSK-3β messenger ribonucleic acid (mRNA) level in the hippocampus of those with depression. However, few studies have investigated GSK-3β activity in the brain of patients with MDD. MethodsaaIn order to test whether patients with MDD have an increase in GSK-3β activity in the brain compared to normal controls, we explored GSK-3β expression level in all brain regions by using the Stanley Neuropathology Consortium Integrative Database (SNCID), which is a web-based method of integrating the Stanley Medical Research Institute data sets. ResultsaaThe level of GSK-3β mRNA expression in the hippocampus was significantly increased in the MDD group (n=8) compared with the control group (n=12, p<0.05). Spearman’s test also reveals that GSK-3β mRNA expression levels were significantly correlated with nitric oxide synthase 1 (NOS1)(ρ=0.70, p<0.0001) and stathmin-like 3 (STMN3)(ρ=0.70, p<0.0001) in the hippocampus. ConclusionaaOur results correspond with the results of previous animal studies that reported increased GSK-3β activity in the hippocampus of those with depression. Our findings also suggest that oxidative stress-induced neuronal cell death and abnormal synaptic plasticity in the hippocampus may play important roles in the pathophysiology of major depression.
Abstract
ObjectiveaaGlycogen synthase kinase-3β (GSK-3β) has become recognized as a broadly influential enzyme affecting diverse range of biological functions, including gene expression, cellular architecture, and apoptosis. The results of previous studies suggest that GSK-3β activity may be increased in the brain of patients with major depressive disorders (MDD). A recent animal study reported increased GSK-3β messenger ribonucleic acid (mRNA) level in the hippocampus of those with depression. However, few studies have investigated GSK-3β activity in the brain of patients with MDD. MethodsaaIn order to test whether patients with MDD have an increase in GSK-3β activity in the brain compared to normal controls, we explored GSK-3β expression level in all brain regions by using the Stanley Neuropathology Consortium Integrative Database (SNCID), which is a web-based method of integrating the Stanley Medical Research Institute data sets. ResultsaaThe level of GSK-3β mRNA expression in the hippocampus was significantly increased in the MDD group (n=8) compared with the control group (n=12, p<0.05). Spearman’s test also reveals that GSK-3β mRNA expression levels were significantly correlated with nitric oxide synthase 1 (NOS1)(ρ=0.70, p<0.0001) and stathmin-like 3 (STMN3)(ρ=0.70, p<0.0001) in the hippocampus. ConclusionaaOur results correspond with the results of previous animal studies that reported increased GSK-3β activity in the hippocampus of those with depression. Our findings also suggest that oxidative stress-induced neuronal cell death and abnormal synaptic plasticity in the hippocampus may play important roles in the pathophysiology of major depression.
참고문헌 (24)
- Embi N, "Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase", Eur J Biochem, 107, pp.519~527 (1980)
- Michelon L, "Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium pro-phylaxis in bipolar disorder", Neurosci Lett, 403, pp.288~293 (2006)
- Hetman M, "Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal", J Neurosci, 20, pp.2567~2574 (2000)
- Klein PS, "A molecular mechanism for the effect of lithium on development", Proc Natl Acad Sci U S A, 93, pp.8455~8459 (1996)
- Gould TD, "AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test", Int J Neuropsychopharmacol, 7, pp.387~390 (2004)
- Kaidanovich-Beilin O, "Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus", Biol Psychiatry, 55, pp.781~784 (2004)
- Li X, "In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain", Neuropsychopharmacology, 29, pp.1426~1431 (2004)
- Karege F, "Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims", Biol Psychiatry, 61, pp.240~245 (2007)
- Tsai SJ, "Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder", Pharmacogenomics J, 8, pp.384~390 (2008)
- Inkster B, "Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder", Arch Gen Psychiatry, 66, pp.721~728 (2009)
- Shapira M, "Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury", Mol Cell Neurosci, 34, pp.571~577 (2007)
- Silva R, "Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta", Neuroscience, 152, pp.656~669 (2008)
- Torrey EF, "The stanley foundation brain collection and neuropathology consortium", Schizophr Res, 44, pp.151~155 (2000)
- Kim S, "Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders", Mol Psychiatry, 15, pp.326~336 (2010)
- Videbech P, "Hippocampal volume and depression: a meta-analysis of MRI studies", Am J Psychiatry, 161, pp.1957~1966 (2004)
- Beurel E, "The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways", Prog Neurobiol, 79, pp.173~189 (2006)
- Andoh T, "Preconditioning regulation of bcl-2 and p66shc by human NOS1 enhances tolerance to oxidative stress", FASEB, 14, pp.2144~2146 (2000)
- Calabrese V, "Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity", Nat Rev Neurosci, 8, pp.766~775 (2007)
- Zhou QG, "Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis", J Neurochem, 103, pp.1843~1854 (2007)
- Oliveira RM, "Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders", Braz J Med Biol Res, 41, pp.333~341 (2008)
- Mistry SJ, "Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy", Mt Sinai J Med, 69, pp.299~304 (2002)
- Shumyatsky GP, "stathmin, a gene enriched in the amygdala, controls both learned and innate fear", Cell, 123, pp.697~709 (2005)
- López-Figueroa AL, "Serotonin 5-HT1A, 5-HT1B, and 5- HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia", Biol Psychiatry, 55, pp.225~233 (2004)
- Kim S, "Postmortem brain tissue for drug discovery in psychiatric research", Schizophr Bull, 35, pp.1031~1033 (2009)